综述

基因组编辑技术在干细胞疾病模型建立和精准医疗中的应用

展开
  • 中国科学院上海生命科学研究院营养科学研究所,上海 200031
韦余达,硕士研究生,专业方向:干细胞肿瘤疾病模型。E-mail: ydwei@sibs.ac.cn

收稿日期: 2015-05-29

  网络出版日期: 2015-10-20

基金资助

上海市浦江人才计划(编号:15PJ1409200)资助

Use of genome editing tools in human stem cell-based disease modeling and precision medicine

Expand
  • Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Shanghai 200031, China

Received date: 2015-05-29

  Online published: 2015-10-20

摘要

精准医疗强调针对不同个体定制个性化治疗方案,其推行需要精准疾病模型的建立。人类干细胞因其具有多能性而成为体外不同类型的成体细胞和器官小体的潜在来源,其强增殖能力保证了充足原材料用于科研分析和大规模药物筛选。基因组编辑技术(尤其是CRISPR/Cas9技术)的快速发展使得在人多能干细胞和成体干细胞中进行高效基因组编辑成为可能。两者的有效结合能建立起针对不同遗传致病背景的“个性化”疾病模型,有利于深入解析不同遗传突变的致病机制和开发高针对性的精准医疗方案。本文对基因组编辑技术在人类干细胞中的应用以及利用干细胞疾病模型模拟罕见病和肿瘤发生的研究进行了综述。

本文引用格式

韦余达, 李爽, 刘改改, 张永贤, 丁秋蓉 . 基因组编辑技术在干细胞疾病模型建立和精准医疗中的应用[J]. 遗传, 2015 , 37(10) : 983 -991 . DOI: 10.16288/j.yczz.15-239

Abstract

Precision medicine emerges as a new approach that takes into account individual variability. The successful conduct of precision medicine requires the use of precise disease models. Human pluripotent stem cells (hPSCs), as well as adult stem cells, can be differentiated into a variety of human somatic cell types that can be used for research and drug screening. The development of genome editing technology over the past few years, especially the CRISPR/Cas system, has made it feasible to precisely and efficiently edit the genetic background. Therefore, disease modeling by using a combination of human stem cells and genome editing technology has offered a new platform to generate “ personalized ” disease models, which allow the study of the contribution of individual genetic variabilities to disease progression and the development of precise treatments. In this review, recent advances in the use of genome editing in human stem cells and the generation of stem cell models for rare diseases and cancers are discussed.

参考文献

[1] Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med , 2015, 372: 793-795.
[2] Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet , 2010, 11(9): 636-646.
[3] Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science , 2009, 326(5959): 1501.
[4] Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science , 2009, 326(5959): 1509-1512.
[5] Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, Bogdanove AJ, Voytas DF. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics , 2010, 186(2): 757-761.
[6] Miller JC, Tan SY, Qiao GJ, Barlow KA, Wang JB, Xia DF, Meng XD, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol , 2010, 29(2): 143-148.
[7] Zhang F, Cong L, Lodato S, Kosuri SK, Church GM, Arlotta P. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol , 2010, 29(2): 149-153.
[8] Cong L, Ran FA, Cox D, Lin SL, Barretto R, Habib N, Hsu PD, Wu XB, Jiang WY, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science , 2013, 339(6121): 819-823.
[9] Mali P, Yang LH, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science , 2013, 339(6121): 823-826.
[10] Jinek M, East A, Cheng A, Lin S, Ma EB, Doudna J. RNA-programmed genome editing in human cells. eLife , 2013, 2, e00471.
[11] Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol , 2013, 31(3): 230-232.
[12] Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell , 2014, 157(6): 1262-1278.
[13] Ding QR, Lee YK, Schaefer EAK, Peters DT, Veres A, Kim K, Kuperwasser N, Motola DL, Meissner TB, Hendriks WT, Trevisan M, Gupta RM, Moisan A, Banks E, Friesen M, Schinzel RT, Xia F, Tang A, Xia YL, Figueroa E, Wann A, Ahfeldt T, Daheron L, Zhang F, Rubin LL, Peng LF, Chung RT, Musunuru K, Cowan CA. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell , 2013, 12(2): 238-251.
[14] Ding QR, Regan SN, Xia YL, Oostrom LA, Cowan CA, Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell , 2013, 12(4): 393-394.
[15] Zou JH, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK, Chen GB, Ye ZH, Park IH, Daley GQ, Porteus MH, Joung JK, Cheng LZ. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell , 2009, 5(1): 97-110.
[16] Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, Katibah GE, Amora R, Boydston EA, Zeitler B, Meng XD, Miller JC, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol , 2009, 27(9): 851-857.
[17] Hockemeyer D, Wang HY, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng XD, Hinkley SJ, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol , 2011, 29(8): 731-734.
[18] Liu GH, Suzuki K, Qu J, Sancho-Martinez I, Yi F, Li M, Kumar S, Nivet E, Kim J, Soligalla RD, Dubova I, Goebl A, Plongthongkum N, Fung HL, Zhang K, Loring JF, Laurent LC, Izpisua Belmonte JC. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell , 2011, 8(6): 688-694.
文章导航

/